Abstract: Eicosapentaenoic acid (EPA) compositions and EPA-rich polar lipids for prophylactic or therapeutic applications are described. Production from certain cultured micro-organisms (like Nitzschia laevis) promotes synthesis of EPA, including polar lipids including EPA. The EPA-rich polar lipids themselves may be used as polar compounds. EPA can be selectively hydrolysed from particular positions in isolated polar lipids by lipase activity, then optionally further purified. The process bypasses reliance on diminishing fish stocks and on physico-chemical processes that may not adequately separate desirable n-3 HUFAs from unwanted products like DHA also found in fish oil and cultured organisms.

Abstract: The invention relates to a microbial biomass composition produced from a heterotrophic fermentation whose fatty acid profile exhibits: an eicosapentaenoic acid (EPA) to arachidonic acid (ARA) ratio of about 11:1 or more; an EPA to total co-concentrating fatty acid ratio of about 8:1 or more, extract compositions, and methods of producing such compositions.

Abstract: The invention relates to a microbial biomass wherein the biomass comprises at least one xanthophyll selected from any one or more of fucoxanthin, diatoxanthin and diadinoxanthin. The invention further relates to a process for producing such a microbial biomass. Further the invention relates to compositions comprising at least one xanthophyll selected from any one or more of fucoxanthin, diatoxanthin and diadinoxanthin and processes for producing such compositions.

Abstract: The invention relates to a microbial biomass composition produced from a heterotrophic fermentation whose fatty acid profile exhibits: an eicosapentaenoic acid (EPA) to arachidonic acid (ARA) ratio of about 11:1 or more; an EPA to total co-concentrating fatty acid ratio of about 8:1 or more, extract compositions, and methods of producing such compositions.

Abstract: Eicosapentaenoic acid (EPA) compositions and EPA-rich polar lipids for prophylactic or therapeutic applications are described. Production from certain cultured micro-organisms (like Nitzschia laevis) promotes synthesis of EPA, including polar lipids including EPA. The EPA-rich polar lipids themselves may be used as polar compounds. EPA can be selectively hydrolysed from particular positions in isolated polar lipids by lipase activity, then optionally further purified. The process bypasses reliance on diminishing fish stocks and on physico-chemical processes that may not adequately separate desirable n-3 HUFAs from unwanted products like DHA also found in fish oil and cultured organisms.

Abstract: Food-providing animals for providing human food rich in at least one of the health-promoting n-3 HUFAs (omega-3 highly unsaturated fatty acids) are selected and then bred so that a greater proportion of dietary n-3 HUFAs and/or their metabolic precursors provided to the animals is conserved in the animals food tissue as n-3 HUFA and transferred into human food. Evidence of heritability, methods for phenotypic or genotypic identification and selection of animals genetically adapted for that function are provided. Animals include farmed mammals and birds, and marine or fresh water animals including fish, crustaceans and molluscs.